



**Pharmacy Services**

**San Francisco Health Plan Pharmacy & Therapeutics Committee**

Wednesday, July 17, 2019

7:30AM – 9:30AM

50 Beale St., 13<sup>th</sup> Floor, San Francisco, CA 94119

<b>Meeting called by:</b>	James Glauber, MD, MPH	<b>Minutes:</b> Luke Nelson (SFHP Pharmacy Analyst) Back-up: Rudy Wu, CPhT (SFHP Pharmacy Specialist)
<b>Meeting Objective:</b>	Vote on proposed formulary and prior authorization(PA) criteria changes	<b>Type of meeting:</b> Quarterly
<b>Attendees:</b>	<p><b>Voting Members:</b></p> <p>James Glauber, MD (SFHP Chief Medical Officer)          Lisa Ghotbi, Pharm. D (SFHP Director of Pharmacy)          Nicholas Jew, MD          Ronald Ruggiero, Pharm. D          Jamie Ruiz, MD          Ted Li, MD          Maria Lopez, Pharm. D          Linda Truong, Pharm. D          Robert (Brad) Williams, MD          Steven Wozniak, MD</p>	<p><b>Others in Attendance:</b></p> <p>Kaitlin Hawkins, Pharm. D (SFHP Pharmacist)          Ralph Crowder, R.Ph (SFHP Pharmacist)          Jessica Shost, Pharm. D (SFHP Pharmacist)          Tammie Chau, Pharm. D (SFHP Pharmacist)          Jenny Nguyen, Pharm. D (SFHP Resident Pharmacist)          Melissa Martinez, CPhT (SFHP Pharmacy Specialist)          Jenna Heath, Pharm. D (PerformRx Pharmacist)          Andrew McDonald, Pharm. D (Walgreens Pharmacist)          Jenna Lester, MD</p> <p><b>Guests:</b></p> <p>Christopher DeSimone, Akcea Therapeutics          Jeannie Timberman, Pfizer          Kelly Wright, Lupin Pharmaceuticals          Marc Rueckert, Pfizer</p>
<b>Members Absent:</b>	Joseph Pace, MD	
<b>Meeting Materials:</b>	<p>Summary of all approved changes are posted under “Materials” section at <a href="https://www.sfhp.org/about-us/committees/pharmacy-and-therapeutics-committee/">https://www.sfhp.org/about-us/committees/pharmacy-and-therapeutics-committee/</a></p> <p>SFHP formulary and prior authorization criteria are located at <a href="https://www.sfhp.org/providers/pharmacy-services/sfhp-formulary/">https://www.sfhp.org/providers/pharmacy-services/sfhp-formulary/</a></p>	

	<b>Topic</b>	<b>Brought By</b>	<b>Discussion</b>	<b>Action</b>
1.	Call to Order	James Glauber, MD	<p>The meeting was called to order at 7:30 am.</p> <ul style="list-style-type: none"> <li>• Conflict of interest check</li> <li>• Agenda overview</li> </ul>	<p>Conflict of Interest checked and instructions given.            Introduction agenda topics done.</p>
2.	Informational Updates	James Glauber, MD Lisa Ghotbi, Pharm. D	<p>Topics:</p> <ul style="list-style-type: none"> <li>• Governor’s Executive Order to carve in the pharmacy benefit               <ul style="list-style-type: none"> <li>◦ SFHP is participating in the stakeholder input process</li> </ul> </li> <li>• SFHP online searchable formulary has been updated</li> </ul>	

	Topic	Brought By	Discussion	Action
			<p>to include prior authorization criteria linked to each applicable drug.</p> <ul style="list-style-type: none"> <li>• New member introductions: <ul style="list-style-type: none"> <li>○ Andrew MacDonald, PharmD, AAHVP: Clinic Store Manager, Walgreens, San Francisco CA</li> <li>○ Jenna C. Lester, MD: Director, Skin of Color Program University of California San Francisco Department of Dermatology</li> </ul> </li> <li>• New pharmacy staff introductions: <ul style="list-style-type: none"> <li>○ Jenny Nguyen, PharmD: Pharmacy Resident, San Francisco Health Plan</li> <li>○ Melissa Martinez, CPhT: Pharmacy Analyst, San Francisco Health Plan</li> <li>○ Luke Nelson: Pharmacy Analyst, San Francisco Health Plan</li> </ul> </li> <li>• Healthy Kids HMO transition <ul style="list-style-type: none"> <li>○ Beginning October 1, 2019, Healthy Kids HMO line of business will be transitioned into Medi-Cal</li> </ul> </li> </ul>	
3.	Review and Approval of April 17, 2019 P&T minutes <i>(pp.5-14 of July 2019 P&amp;T Packet)</i>	James Glauber, MD	The committee approved the minutes as presented.	<p><b>VOTE:</b> <b><u>Review and Approval of April 17, 2019 P&amp;T Minutes</u></b> Approved recommendations as presented.</p> <p><i>Vote: Unanimous approval (10/10)</i></p>
<p><b>****Adjourn to Closed Session****</b> Closed Session pursuant to Welfare and Institutions Code Section 14087.36 (w)</p>				
4.	<p>Discussion and Recommendation for Change to SFHP Formulary and Prior Authorization Criteria for Select Drug Classes.</p> <p><b><u>Formulary Maintenance Items:</u></b> <b><u>Dermatology:</u></b> Acne &amp; Rosacea <i>(pp.17-20 of July 2019 P&amp;T Packet)</i></p>	Kaitlin Hawkins, Pharm. D	<p><i>The following drug classes were reviewed for pertinent literature (including meta-analyses and pivotal clinical trials), guideline updates, and drug additions to or removals from market since last class review.</i></p> <p><i>Major recommendations included the following:</i></p> <p><b>Last reviewed:</b> July 2018/July 2017</p> <p><b>Formulary Update:</b> (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO, &amp; Healthy San Francisco)</p> <ul style="list-style-type: none"> <li>• Add adapalene 0.1% cream to formulary tier 3 based on requests and comparative cost effectiveness; step therapy required (Differin® OTC and tretinoin cream/gel) and age limit (AL), quantity limit (QL) to align with other strengths</li> <li>• Remove unutilized BP products from formulary due to lack of utilization and alternatives available</li> </ul> <p><b>Prior Authorization Criteria Update:</b></p> <ul style="list-style-type: none"> <li>• Update Topical Antibiotics and Benzoyl Peroxide criteria to include additional non-formulary combinations and add criteria for clindamycin/tretinoin combination</li> </ul>	<p><b>VOTE:</b> <b><u>Formulary Maintenance Items</u></b> Approved recommendations as presented.</p> <p><i>Vote: Unanimous approval (10/10)</i></p>

	Topic	Brought By	Discussion	Action
			<ul style="list-style-type: none"> <li>Update Topical Retinoids criteria to include additional non-formulary topical retinoids</li> </ul> <p><b>Drug Utilization Review Update:</b></p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>Committee Discussion:</b> <i>The committee had no comments or questions.</i></p>	
5.	<p><b>Formulary Maintenance Items:</b> <u>Gastroenterology:</u> Ammonia Inhibitors <i>(pp.21-22 of July 2019 P&amp;T Packet)</i></p>	Kaitlin Hawkins, Pharm. D	<p><b>Last reviewed:</b> July 2017 <b>Formulary Update:</b> (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO &amp; Healthy San Francisco)</p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>Prior Authorization Criteria Update:</b></p> <ul style="list-style-type: none"> <li>None (no active criteria)</li> </ul> <p><b>Drug Utilization Review Update:</b></p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>Committee Discussion:</b> <i>The committee had no comments or questions.</i></p>	
6.	<p><b>Formulary Maintenance Items:</b> <u>Gastroenterology:</u> Anorexia &amp; Weight Gain <i>(pp.23-24 of July 2019 P&amp;T Packet)</i></p>	Kaitlin Hawkins, Pharm. D	<p><b>Last reviewed:</b> July 2017 <b>Formulary Update:</b> (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO &amp; Healthy San Francisco)</p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>Prior Authorization Criteria Update:</b></p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>Drug Utilization Review Update:</b></p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>Committee Discussion:</b> <i>The committee had no comments or questions.</i></p>	
7.	<p><b>Formulary Maintenance Items:</b> <u>Gastroenterology:</u> Antiemetics <i>(pp.25-27 of July 2019 P&amp;T Packet)</i></p>	Kaitlin Hawkins, Pharm. D	<p><b>Last reviewed:</b> July 2017 <b>Formulary Update:</b> (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO &amp; Healthy San Francisco)</p> <ul style="list-style-type: none"> <li>Add OTC dimenhydrinate to formulary (Medi-Cal only)</li> </ul> <p><b>Prior Authorization Criteria Update:</b></p> <ul style="list-style-type: none"> <li>Update Diclegis® criteria to include Bonjesta® and rename criteria</li> </ul> <p><b>Drug Utilization Review Update:</b></p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>Committee Discussion:</b> <i>The committee discussed and clarified that all olanzapine is carved out to Fee-For-Service for Medi-Cal regardless of indication.</i></p>	
8.	<p><b>Formulary Maintenance Items:</b> <u>Endocrinology:</u> Thyroid Disorders <i>(pp.28-29 of July 2019 P&amp;T Packet)</i></p>	Kaitlin Hawkins, Pharm. D	<p><b>Last reviewed:</b> April 2017 <b>Formulary Update:</b> (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO &amp; Healthy San Francisco)</p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>Prior Authorization Criteria Update:</b></p>	

	Topic	Brought By	Discussion	Action
			<ul style="list-style-type: none"> <li>• None (no active criteria)</li> </ul> <p><b>Drug Utilization Review Update:</b></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><b>Committee Discussion:</b>  <i>The committee had no comments or questions.</i></p>	
9.	<p><b>Formulary Maintenance Items:</b>  <u>Infectious Disease:</u> Hepatitis B  (pp.30-31 of July 2019 P&amp;T Packet)</p>	Kaitlin Hawkins, Pharm. D	<p><b>Last reviewed:</b> April 2017</p> <p><b>Formulary Update:</b>  (Healthy Kids HMO &amp; Healthy Workers HMO)</p> <ul style="list-style-type: none"> <li>• Add Vemlidy® (tenofovir alafenamide) to formulary based on utilization and guideline recommendations, but require prior authorization due to cost-effective alternatives available</li> <li>• Remove Epivir® HBV (lamivudine) oral solution from formulary due to lack of utilization and preferred alternatives available</li> </ul> <p><b>Prior Authorization Criteria (PA) Recommendations:</b></p> <ul style="list-style-type: none"> <li>• Update Hepatitis B criteria to reflect formulary changes above</li> </ul> <p><b>Drug Utilization Review (DUR) Recommendations:</b></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><b>Committee Discussion:</b>  <i>The committee discussed availability of Viread generic tenofovir DF at pharmacies. It was determined that research would be done to confirm pharmacies are able to order the generic. The committee discussed and confirmed that all drugs are carved out to Fee-For-Service for Medi-Cal regardless of indication, and formulary and changes pertain to Healthy Kids HMO &amp; Healthy Workers HMO.</i></p>	
10.	<p><b>Formulary Maintenance Items:</b>  <u>Hematology:</u> Iron and Chelators  (pp.32-34 of July 2019 P&amp;T Packet)</p>	Kaitlin Hawkins, Pharm. D	<p><b>Last reviewed:</b> January 2017</p> <p><b>Formulary Update:</b>  (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO &amp; Healthy San Francisco)</p> <ul style="list-style-type: none"> <li>• Remove the following OTC supplements from formulary due to no utilization: <ul style="list-style-type: none"> <li>○ Slow Release Iron 142 mg ER tablet</li> <li>○ Ferrous fumarate/Vitamin C/Vitamin B12/folic acid 200 mg-250 mg-0.01 mg-1 mg capsule</li> <li>○ Ferrous fumarate/Vitamin C/Vitamin B12/folic acid 460 mg-60 mg-0.01 mg-1 mg capsule</li> <li>○ Vitafof® (iron/calcium/Vitamin E/folic acid/MVI) 65 mg-1 mg tablet</li> </ul> </li> </ul> <p><b>PA Criteria Recommendations:</b></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><b>DUR Recommendations:</b></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><b>Committee Discussion:</b></p>	

	Topic	Brought By	Discussion	Action
			<i>The committee had no comments or questions.</i>	
11.	<b><u>Endocrinology</u></b> Anti-Obesity Class Review (pp.35-46 of July 2019 P&T Packet)	Jenna Heath, Pharm. D	<i>The plan presented class reviews, miscellaneous changes and recommendations for Endocrinology medications. Major recommendations include the following:</i> <b>Formulary Recommendations:</b> (Medi-Cal & Healthy San Francisco) <ul style="list-style-type: none"> <li>Remove prior authorization requirement for OTC Alli® (orlistat) due to low risk profile and cost-effectiveness</li> </ul> <b>Prior Authorization Criteria Recommendations:</b> <ul style="list-style-type: none"> <li>Update Anti-obesity Medications criteria to include appropriate quantity limits for all applicable drugs, and to include criteria for non-formulary medications requiring trial/failure of two formulary alternatives</li> </ul> <b>DUR Recommendations:</b> <ul style="list-style-type: none"> <li>None</li> </ul> <b>Committee Discussion:</b> <i>The committee had no comments or questions.</i>	<b>VOTE:</b> <b><u>Endocrinology</u></b> Approved recommendations as presented.  <b><u>Anti-Obesity Class Review</u></b>  <i>Vote: Unanimous approval (10/10)</i>
12.	<b><u>Endocrinology</u></b> Hormone Replacement Therapy Review (pp.47-59 of July 2019 P&T Packet)	Jenna Heath , Pharm. D	<b>Formulary Recommendations:</b> <u>(Medi-Cal, Healthy Kids HMO, Healthy Workers HMO &amp; Healthy San Francisco)</u> <ul style="list-style-type: none"> <li>None</li> </ul> <b>PA Criteria Recommendations:</b> <ul style="list-style-type: none"> <li>None; no active criteria</li> </ul> <b>DUR Recommendations:</b> <ul style="list-style-type: none"> <li>Conduct a full DUR report analyzing HRT duration of use, agent choice, and agent dose in addition to member age and reported gender</li> </ul> <b>Committee Discussion:</b> <i>The committee had no comments or questions.</i>	<b>VOTE:</b> <b><u>Endocrinology</u></b> No vote required due to no change recommended; committee supported further DUR analysis.  <b><u>Hormone Replacement Therapy Review</u></b>  <i>Vote: n/a</i>
13.	<b><u>Endocrinology</u></b> Diabetes: Miscellaneous Change (pp.60-63 of July 2019 P&T Packet)	Jenna Heath, Pharm. D	<b>Formulary Recommendations:</b> <u>(Medi-Cal, Healthy Kids HMO, Healthy Workers HMO &amp; Healthy San Francisco)</u> <ul style="list-style-type: none"> <li>Remove Januvia® and Janumet®/XR from formulary and grandfather all current users</li> </ul> <b>PA Criteria Recommendations:</b> <ul style="list-style-type: none"> <li>Update DPP-4 Inhibitors criteria based on formulary changes above</li> </ul> <b>DUR Recommendations:</b> <ul style="list-style-type: none"> <li>None</li> </ul> <b>Committee Discussion:</b> <i>The committee discussed formulary options in other</i>	<b>VOTE:</b> <b><u>Endocrinology</u></b> Approved recommendations as presented.  <b><u>Diabetes: Miscellaneous Change</u></b>  <i>Vote: Unanimous approval (10/10)</i>

	Topic	Brought By	Discussion	Action
			<p>classes, including glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors. The committee confirmed that SFHP formulary contains options in each class with step therapy (metformin) required, as well as maintaining the preferred formulary DPP-4 inhibitor alogliptin and its combinations.</p>	
14.	<p><b><u>Gastroenterology</u></b> Constipation &amp; Irritable Bowel Syndrome Class Review (pp.64-78 of July 2019 P&amp;T Packet)</p>	Jenna Heath, Pharm. D	<p>The plan presented a class review and recommendations for Gastroenterology medications. Major recommendations include the following: <b>Formulary Recommendations:</b> (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO &amp; Healthy San Francisco) • None <b>PA Criteria Recommendations:</b> • Update Constipation Agents criteria with new labeled indications, and to remove Amitiza® as pre-requisite to receive Relistor® for OIC based on 2019 guidelines <b>DUR Recommendations:</b> • None <b>Committee Discussion:</b> The committee had no comments or questions.</p>	<p><b>VOTE:</b> <b><u>Gastroenterology</u></b> Approved recommendations as presented.  <b><u>Constipation &amp; Irritable Bowel Syndrome Class Review</u></b>  <u>Vote:</u> Unanimous approval (10/10)</p>
15.	<p><b><u>Nephrology</u></b> Chronic Kidney Disease: Mineral Bone Disorder Class Review (pp.79-91 of July 2019 P&amp;T Packet)</p>	Kaitlin Hawkins, Pharm. D	<p>The plan presented a class review, monograph and recommendations for Nephrology medications. Major recommendations include the following: <b>Formulary Recommendations:</b> (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO &amp; Healthy San Francisco) • Remove prior authorization requirement from sevelamer carbonate tablet due to cost-effectiveness and high PA volume and approval rate • Add age limit to Phoslyra® (calcium acetate) oral solution to ensure appropriate pediatric use • Remove doxercalciferol capsule from formulary due to lack of utilization and limited place in therapy <b>PA Criteria Recommendations:</b> • Update Phosphate Binders criteria to reflect formulary changes above • Update Sensipar® (cinacalcet) criteria to remove requirement of calcitriol/vitamin D based on guidelines <b>DUR Recommendations:</b> • Develop provider communication to highlight cost and formulary status distinctions between sevelamer carbonate (Renvela®) versus hydrochloride (Renagel®) <b>Committee Discussion:</b> The committee had no comments or questions.</p>	<p><b>VOTE:</b> <b><u>Nephrology</u></b> Approved recommendations as presented.  <b><u>Chronic Kidney Disease: Mineral Bone Disorder Class Review</u></b>  <u>Vote:</u> Unanimous approval (10/10)</p>

	Topic	Brought By	Discussion	Action
16.	<b><u>Nephrology</u></b> Galafold® (migalastat) Monograph (pp.92-97 of July 2019 P&T Packet)	Jenna Heath, Pharm. D	<b>Formulary Recommendations:</b> (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO & Healthy San Francisco) <ul style="list-style-type: none"> <li>Maintain as non-formulary at this time</li> </ul> <b>PA Criteria Recommendations:</b> <ul style="list-style-type: none"> <li>None</li> </ul> <b>DUR Recommendations:</b> <ul style="list-style-type: none"> <li>None</li> </ul> <b>Committee Discussion:</b> <i>The committee had no comments or questions.</i>	<b>VOTE:</b> <b><u>Nephrology</u></b> Approved recommendations as presented.  <b><u>Galafold® (migalastat) Monograph</u></b>  <i>Vote: Unanimous approval (10/10)</i>
17.	<b><u>Neurology</u></b> Diacomit® (stiripentol) Monograph (pp.98-103 of July 2019 P&T Packet)	Jenna Heath, Pharm. D	<i>The plan presented monographs and recommendations for Neurology medications.</i> <i>Major recommendations include the following:</i> <b>Formulary Recommendations:</b> (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO & Healthy San Francisco) <ul style="list-style-type: none"> <li>Maintain as non-formulary at this time</li> </ul> <b>PA Criteria Recommendations:</b> <ul style="list-style-type: none"> <li>None</li> </ul> <b>DUR Recommendations:</b> <ul style="list-style-type: none"> <li>None</li> </ul> <b>Committee Discussion:</b> <i>The committee had no comments or questions.</i>	<b>VOTE:</b> <b><u>Neurology</u></b> Approved recommendations as presented.  <b><u>Diacomit® (stiripentol) Monograph</u></b>  <i>Vote: Unanimous approval (10/10)</i>
18.	<b><u>Neurology</u></b> Firdapse® (amifampridine) Monograph (pp.104-109 of July 2019 P&T Packet)	Jenna Heath, Pharm. D	<b>Formulary Recommendations:</b> (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO & Healthy San Francisco) <ul style="list-style-type: none"> <li>Maintain as non-formulary at this time</li> </ul> <b>PA Criteria Recommendations:</b> <ul style="list-style-type: none"> <li>None</li> </ul> <b>DUR Recommendations:</b> <ul style="list-style-type: none"> <li>None</li> </ul> <b>Committee Discussion:</b> <i>The committee had no comments or questions.</i>	<b>VOTE:</b> <b><u>Neurology</u></b> Approved recommendations as presented.  <b><u>Firdapse® (amifampridine) Monograph</u></b>  <i>Vote: Unanimous approval (10/10)</i>
19.	<b><u>Neurology</u></b> Mavenclad® (cladribine) and Mayzent® (siponimod) Dual Monograph (pp.110-121 of July 2019 P&T Packet)	Kaitlin Hawkins, Pharm. D	<b>Formulary Recommendations:</b> (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO & Healthy San Francisco) <ul style="list-style-type: none"> <li>Add Mavenclad® (cladribine) to formulary tier 4 with prior authorization required to ensure appropriate diagnosis (relapsing multiple sclerosis in adults with adequate response or intolerant to other therapies)</li> </ul> <b>PA Criteria Recommendations:</b> <ul style="list-style-type: none"> <li>Update Multiple Sclerosis criteria to include new therapies</li> </ul> <b>DUR Recommendations:</b> <ul style="list-style-type: none"> <li>None</li> </ul> <b>Committee Discussion:</b> <i>The committee had no comments or questions.</i>	<b>VOTE:</b> <b><u>Neurology</u></b> Approved recommendations as presented.  <b><u>Mavenclad® (cladribine) and Mayzent® (siponimod) Dual Monograph</u></b>  <i>Vote: Unanimous approval (10/10)</i>

	Topic	Brought By	Discussion	Action
20.	<p><b>Otorhinolaryngology</b> Allergy Cold &amp; Cough Abbreviated Review (pp.122-139 of July 2019 P&amp;T Packet)</p>	Kaitlin Hawkins, Pharm. D	<p>The plan presented a class review and recommendations for Otorhinolaryngology medications. Major recommendations include the following: <b>Formulary Recommendations:</b> (Medi-Cal, Healthy Kids HMO, Healthy Workers HMO &amp; Healthy San Francisco: Rx Products)</p> <ul style="list-style-type: none"> <li>• Remove flunisolide nasal spray from formulary due to cost-effective alternatives available (grandfather any chronic users)</li> </ul> <p>(Medi-Cal &amp; Healthy San Francisco: OTC Products)</p> <ul style="list-style-type: none"> <li>• Add the following drugs to formulary tier 1 due to utilization and comparative cost-effectiveness: <ul style="list-style-type: none"> <li>○ cetirizine 5,10mg chewable tablet</li> <li>○ fexofenadine 30mg orally disintegrating tabs</li> </ul> </li> <li>• Add guaifenesin 1200mg 12h ER tablet to formulary tier 1 with age limit <math>\geq 2</math> years old to align with other strengths [already tier 1 for C-Wrap]</li> <li>• Remove Neo-Tuss® (guaifenesin-DM®) 200-30mg/5mL liquid from formulary due to lack of utilization and formulary alternatives available</li> <li>• Remove pseudoephedrine-codeine-guaifenesin 30mg-10mg-100mg syrup from formulary due to lack of utilization and formulary alternatives available</li> <li>• Add age limits to the following drugs based on labeled dosing and AAP/FDA safety recommendations, without grandfathering (due to as-needed use): <ul style="list-style-type: none"> <li>○ guaifenesin-dextromethorphan 100mg-10mg/5mL syrup and liquid and 200mg-10mg/5mL liquid (<math>\geq 2</math> years old)</li> <li>○ guaifenesin 100mg/5mL liquid, 200mg IR tablet, and 600mg 12h ER tablet (<math>\geq 2</math> years old)</li> <li>○ dextromethorphan polisterex (Delsym®) 30mg/5mL 12h ER suspension (<math>\geq 4</math> years old)</li> <li>○ pseudoephedrine 30mg, 60mg IR tablet, 120mg ER tablet, 15mg/5mL and 30mg/5mL oral liquid (<math>\geq 4</math> years old)</li> <li>○ chlorpheniramine-pseudoephedrine-dextromethorphan (Pedia Relief®) 1-15-5mg/5mL liquid (<math>\geq 6</math> years old)</li> <li>○ triprolidine-pseudoephedrine 2.5mg-60mg tablet (<math>\geq 6</math> years old)</li> <li>○ guaifenesin-pseudoephedrine (Mucinex® D) 600mg-60mg 12h ER tablet (<math>\geq 6</math> years old)</li> <li>○ loratadine-pseudoephedrine (Claritin® D) 5mg-120mg ER 12h tablet and 10mg-240mg ER 24h tablet (<math>\geq 12</math> years old)</li> </ul> </li> </ul>	<p><b>VOTE:</b> <b>Otorhinolaryngology</b> Approved recommendations as presented.</p> <p><b><u>Allergy Cold &amp; Cough Abbreviated Review</u></b></p> <p><i>Vote: Unanimous approval (10/10)</i></p>



	Topic	Brought By	Discussion	Action
			<p><b>PA Criteria Recommendations:</b></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><b>DUR Recommendations:</b></p> <ul style="list-style-type: none"> <li>• Review member-level chronic use of non-formulary promethazine-codeine as per grandfathering logic and assess for any changes to logic</li> </ul> <p><b>Committee Discussion:</b></p> <p><i>The committee commented on the possible use of 1<sup>st</sup> generation antihistamines for anxiety and/or insomnia; indication information is not included in pharmacy claims data.</i></p> <p><i>The committee had a discussion regarding sugar-free products. It was determined to evaluate products for sugar-free status in future reviews.</i></p> <p><i>The committee discussed interaction between protease inhibitors (PIs) for HIV and certain nasal steroids; it was confirmed that options that do not interact with PIs remain on formulary without restriction.</i></p>	
21.	<p>Drug Utilization Review (DUR)</p> <ul style="list-style-type: none"> <li>• Retrospective Program Reports</li> <li>• Prospective Program Reports</li> </ul> <p><i>(pp.140-157 of July 2019 P&amp;T Packet)</i></p>	<p>Jessica Shost, Pharm. D Kaitlin Hawkins, Pharm. D</p>	<p><i>The plan presented DUR program updates and reports for committee review and discussion</i></p> <p>Retrospective Program Reports</p> <ul style="list-style-type: none"> <li>• Initial Short-Acting Opioid Rx 7-Day Limit: One Year Impact Analysis</li> <li>• Adherence to Biologic DMARDs Used to Treat Rheumatoid Arthritis</li> </ul> <p>Prospective Program Reports:</p> <ul style="list-style-type: none"> <li>• Prospective DUR quarterly report Q1.2019</li> </ul> <p><b>Committee Discussion:</b></p> <p><i>The committee had a discussion clarifying denial errors (“hard”), which reject at point of service, versus report-only errors (“soft”), which allow the pharmacist to review the error but process at point of service.</i></p>	<p><i>Non-Voting Items</i></p>
22.	<p>Medication Therapy Management</p> <p><i>(pp.158-166 of July 2019 P&amp;T Packet)</i></p>	<p>Tammie Chau, Pharm. D</p>	<p>Medication Therapy Management (MTM) Program 2018 Program Summary and Results</p> <ul style="list-style-type: none"> <li>• SFHP Pharmacists are involved in optimizing medication regimens for members engaged in Care Management program, supporting medication knowledge, and meeting regulatory expectations.</li> <li>• MTM program is collaborative, effective, and impactful for members with complex chronic conditions.</li> <li>• Providers can refer members to Care Management program.</li> </ul> <p><i>The committee had a discussion on the requirements to qualify for the Care Management program, and options for provider referral.</i></p>	<p><i>Non-Voting Item</i></p>
<b>****RECONVENE IN OPEN SESSION****</b>				
23.	<p>Summary of Closed Session</p>	<p>James Glauber, MD</p>	<p>Reconvened Open session around 9:25 am</p>	<p><i>Non-voting item</i></p>

	Topic	Brought By	Discussion	Action
24.	Annual Pharmacy Policies and Procedures (P&Ps) Review (pp.167-181 of July 2019 P&T Packet)	Ralph Crowder, RPh	<p>The plan presented changes to the Pharmacy Policies and Procedures (P&amp;P) for P&amp;T committee annual review and approval:</p> <p><b>Pharm-02: Pharmacy Prior Authorization</b></p> <p><b>Document Changes:</b></p> <ul style="list-style-type: none"> <li>Added clarifying language to section 2 regarding individualized care</li> </ul> <p><b>Pharm-14: Drug Utilization Review (DUR) Program</b></p> <p><b>Document Changes:</b></p> <ul style="list-style-type: none"> <li>Clarified narrow therapeutic window drugs/classes in section A.1</li> <li>Clarified language in section A.6 to reflect current benefit design regarding days' supply</li> <li>Clarified report frequency in section B.2</li> <li>Added Pharm-15 as a related policy</li> </ul> <p><b>Committee Discussion:</b></p> <p>The committee had no comments or questions.</p>	<p><b>VOTE:</b></p> <p><b><u>Review and Approval of Annual Pharmacy Policies and Procedures (P&amp;Ps)</u></b></p> <p>Approved recommendations as presented.</p> <p><i>Vote: Unanimous approval (10/10)</i></p>
25.	Review and Approval of Interim Prior Authorization Criteria Changes (pg.182 July 2019 P&T Packet)	Kaitlin Hawkins, Pharm. D	<p>The plan presented Prior Authorization Criteria interim changes (New Criteria, Revised Existing Criteria &amp; a table of criteria that were evaluated per the Annual review process where no clinical changes were made) for review and approval</p> <p><b>Committee Discussion:</b></p> <p>The committee had no comments or questions.</p>	<p><b>VOTE:</b></p> <p><b><u>Review and Approval of Interim Prior Authorization Criteria Changes</u></b></p> <p>Approved recommendations as presented.</p> <p><i>Vote: Unanimous approval (10/10)</i></p>
26.	Review and Approval of Interim Formulary Changes and Formulary Placement for New Drugs to Market (pp.183-186 of July 2019 P&T Packet)	Kaitlin Hawkins, Pharm. D	<p>The plan presented interim formulary changes and formulary status for new drugs to market.</p> <p><b>Committee Discussion:</b></p> <p>The committee had no comments or questions.</p>	<p><b>VOTE:</b></p> <p><b><u>Review and Approval of Interim Formulary Changes and Formulary Placement for New Drugs to Market</u></b></p> <p>Approved recommendations as presented.</p> <p><i>Vote: Unanimous approval (10/10)</i></p>
25.	Informational Update on New Developments in the Pharmacy Market (pp.187-193 of July 2019 P&T Packet)	Jenna Heath, Pharm. D	<p>The plan provided information on new developments in the pharmacy market.</p>	<p>Non-voting item</p>
23.	Adjournment	James Glauber, MD	<p>The meeting adjourned at 9:30 am.</p> <p>2019 – 2020 P&amp;T Committee Meeting dates are:</p> <ul style="list-style-type: none"> <li>Wednesday, October 16, 2019</li> <li>Wednesday, January 15, 2020</li> <li>Wednesday, April 15, 2020</li> <li>Wednesday, July 15, 2020</li> </ul>	

Respectfully submitted by:

A handwritten signature in blue ink that reads "James Glauber". The signature is written in a cursive style with a large initial "J".

August 23, 2019

---

James Glauber, MD, MPH  
Chief Medical Officer

---

Date